Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00974051 · ClinicalTrials.gov registry record · NA
Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00974051 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 16 participants.
The verdict
NCT00974051, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session. This is a randomized three period cross-over study including treatment with Terbutaline, a 20% basal reduction for six hours, or no treatment (control).
Interventions
- OTHER Control
- DRUG Terbutaline
- OTHER 20% basal insulin reduction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00974051
The ClinicalTrials.gov registry entry for NCT00974051 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Control is the first listed.
NCT00974051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00974051 about?
NCT00974051 is a clinical study titled "Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia". The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session. This is a randomized three period cross-over study including treatment with Terbutaline, a 20% basal reduction for si...
What is the current status of trial NCT00974051?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2008-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00974051?
The interventions under investigation include: Control (OTHER), Terbutaline (DRUG), 20% basal insulin reduction (OTHER).
Who is sponsoring clinical trial NCT00974051?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.